Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

Investors bet against new drug launches because the shift from a research-focused culture to a commercial one is seen as an 'unnatural transition.' Companies are graded harshly on early results, creating a predictable valuation dip that hedge funds exploit, as seen with Portola Pharmaceuticals.

The biotech industry recently endured its own "dot-com bust." Post-COVID hype gave way to investor impatience with the sector's fundamental realities: it takes over 10 years and massive capital ($200B/year industry-wide) to get a drug approved, leading to a sharp market correction.

Early-stage biotech companies are vulnerable to short selling in public markets because their experiments run for 12-24 months, creating long periods without news flow. With no catalysts to drive buying ("no bid"), hedge funds can short the stocks until data is released, highlighting a structural disadvantage of being public too early.

A significant divergence in sentiment is emerging in the biotech market. While professional money managers are nervous about the recent rally being overextended and ripe for a pullback, retail investors are returning with a giddy, 'can't lose' mentality. This juxtaposition of caution and euphoria signals a potentially volatile and dangerous market environment.

In a capital-constrained market, positive clinical data can trigger a stock drop for biotechs with insufficient cash. The scientific success highlights an immediate need for a highly dilutive capital raise, which investors price in instantly. Having over two years of cash is now critical to realizing value.

Despite a strong year for biotech, investors are showing signs of fatigue. This leads them to sell stocks immediately after positive news and financing rounds to lock in gains before year-end, rather than letting positive momentum build further.

Even with strong initial sales, Soleno's stock was punished due to a growing investor fear of the 'launch plateau.' Citing examples like Skyclaris, the market is now skeptical that a few good quarters can be sustained, discounting strong early performance and demanding proof of long-term growth trajectory before rewarding a stock.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.